Rituximab for Multiple Sclerosis
Annette Langer‐Gould, Elias S. Sotirchos, Dennis Bourdette
Abstract
Yet not much has changed. Food and Drug Administration (FDA)-approved MS disease-modifying therapies continue to generate enormous profits for pharma, and rituximab remains hidden in plain sight.
Topics & Concepts
Multiple sclerosisRituximabMedicineClinical neurologyFamily medicineIntensive care medicineImmunologyPsychologyAntibodyNeuroscienceMultiple Sclerosis Research StudiesAcute Lymphoblastic Leukemia researchMacrophage Migration Inhibitory Factor